266 related articles for article (PubMed ID: 33939321)
1. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X
Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321
[TBL] [Abstract][Full Text] [Related]
2. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
3. The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.
Wang Z; Chen W; Zuo L; Xu M; Wu Y; Huang J; Zhang X; Li Y; Wang J; Chen J; Wang H; Sun H
Cancer Commun (Lond); 2022 Mar; 42(3):245-265. PubMed ID: 35234370
[TBL] [Abstract][Full Text] [Related]
4. EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells.
Shen X; Jin X; Fang S; Chen J
Cell Mol Biol Lett; 2023 Jul; 28(1):53. PubMed ID: 37420173
[TBL] [Abstract][Full Text] [Related]
5. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
8. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
11. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
13. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Xue C; Xu Y; Ye W; Xie Q; Gao H; Xu B; Zhang D; Jiang J
Gynecol Oncol; 2020 Apr; 157(1):222-233. PubMed ID: 31987601
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
[TBL] [Abstract][Full Text] [Related]
15. The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun.
Yu P; Wei H; Li K; Zhu S; Li J; Chen C; Zhang D; Li Y; Zhu L; Yi X; Liu N; Liu P; Zhao S; Chen X; Peng C
J Exp Clin Cancer Res; 2022 Dec; 41(1):346. PubMed ID: 36522774
[TBL] [Abstract][Full Text] [Related]
16. The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Chen JX; Yi XJ; Gao SX; Sun JX
Gen Physiol Biophys; 2020 Jul; 39(4):319-330. PubMed ID: 32902402
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells.
Jang YS; Kim TW; Ryu JS; Kong HJ; Jang SH; Nam GH; Kim JH; Jeon S
PLoS One; 2023; 18(2):e0277285. PubMed ID: 36757936
[TBL] [Abstract][Full Text] [Related]
18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
19. Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
Li Y; Amaladas N; O'Mahony M; Manro JR; Inigo I; Li Q; Rasmussen ER; Brahmachary M; Doman TN; Hall G; Kalos M; Novosiadly R; Puig O; Pytowski B; Schaer DA
PLoS One; 2022; 17(7):e0268244. PubMed ID: 35849586
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral Delivery of an Adenoviral Vector Carrying the
Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
